Real World Treatment Patterns and Outcomes of Venetoclax (Ven) and Hypomethylating Agents (HMA) in Patients with Newly Diagnosed Acute Myeloid Leukemia (AML) in the United States

被引：1
|
作者：
Vachhani, Pankit [1 ]
Abbas, Jonathan A. [2 ]
Flahavan, Evelyn M. [3 ]
Ma, Esprit [4 ]
Xu, Tao [5 ]
Jin, Huan [4 ]
Montez, Melissa [4 ]
Huang, Weize [4 ]
Gershon, Anda [4 ]
Ku, Grace [4 ]
Flores, Brannon [4 ]
Onishi, Maika [4 ]
Bui, Cat N. [6 ]
Donnellan, William [2 ]
机构：
[1] UAB, ONeal Comprehens Canc Ctr, Birmingham, AL USA
[2] Tennessee Oncol, Nashville, TN USA
[3] Roche Prod Ltd, Welwyn Garden City, Herts, England
[4] Genentech Inc, San Francisco, CA 94080 USA
[5] F Hoffmann La Roche Ltd, Basel, Switzerland
[6] AbbVie Inc, N Chicago, IL USA
来源：
BLOOD | 2021年 / 138卷
关键词：
D O I：
10.1182/blood-2021-147851
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页数：6
相关论文
共 50 条
  • [21] A Retrospective Observational Real-World Study of the Characteristics, Genomic Analysis, Treatment Patterns and Outcomes of Patients (Pts) with Newly Diagnosed (ND) Acute Myeloid Leukemia (AML) in the United States
    Byrd, John C.
    Gatz, Jennifer L.
    Cripe, Larry D.
    Louis, Cynthia Lim
    Mims, Alice S.
    Borate, Uma
    Yocum, Ashley O.
    Gana, Theophilus
    Burd, Amy
    BLOOD, 2021, 138
  • [22] Intensive Induction Chemotherapy (IC) Vs Hypomethylating Agents plus Venetoclax (HMA/VEN) in IDH1-or IDH2-Mutant Newly Diagnosed Acute Myeloid Leukemia ( AML) - a Multicenter Cohort Study
    Bewersdorf, Jan Philipp
    Shimony, Shai
    Shallis, Rory M.
    Liu, Yiwen
    Schaefer, Eva Johanna
    Zeidan, Amer M.
    Goldberg, Aaron D.
    Stein, Eytan M.
    Marcucci, Guido
    Lindsley, R. Coleman
    Chen, Evan C.
    Ramos, Jorge
    Stein, Anthony Selwyn
    DeAngelo, Daniel J.
    Neuberg, Donna S.
    Stone, Richard M.
    Ball, Brian J.
    Stahl, Maximilian
    BLOOD, 2023, 142
  • [23] Real-World Treatment Patterns Among Patients with Newly Diagnosed (ND) Acute Myeloid Leukemia (AML) with TP53 Mutation in the United States (US)
    Bystrom, Rebecca
    Fernandes, Laura L.
    Wynne, Joseph
    Pulte, Dianne
    Hansen, Eric
    Belli, Andrew J.
    Barcellos, Anna
    Zettler, Christina M.
    Vallejo, Jonathon
    Norsworthy, Kelly
    De Claro, Angelo
    Lerro, Catherine
    Theoret, Marc R.
    Wang, Ching-Kun
    Rivera, Donna
    BLOOD, 2023, 142
  • [24] Real-World Treatment Experience of Venetoclax in Combination with Hypomethylating Agents in Patients with Newly Diagnosed Acute Myeloid Leukemia: Updated Experience from a Predominately Community Setting in the US
    Vachhani, Pankit
    Ma, Esprit
    Xu, Tao
    Montez, Melissa
    Worth, Sarah
    Cheng, Wei-Han
    Werner, Michael
    Abbas, Jonathan
    Donnellan, William
    BLOOD, 2022, 140
  • [25] Real-World Treatment Patterns, Healthcare Resource Utilization, and Costs in Patients with Newly Diagnosed Acute Myeloid Leukemia (AML)
    Stein, Eytan M.
    Latremouille-Viau, Dominick
    Guerin, Annie
    Shi, Sherry
    Gagnon-Sanschagrin, Patrick
    Bonifacio, Gaetano
    Joseph, George J.
    BLOOD, 2016, 128 (22)
  • [26] Real world outcomes among patients with newly diagnosed acute myeloid leukemia
    Pulte, Elizabeth D.
    Fernandes, Laura L.
    Wynne, Joseph
    Hansen, Eric
    Belli, Andrew J.
    Barcellos, Anna
    Zettler, Christina M.
    Bystrom, Rebecca
    Vallejo, Jonathon
    Gu, Wenjuan
    Lerro, Catherine
    Norsworthy, Kelly
    DeClaro, Angelo
    Theoret, Marc R.
    Rivera, Donna
    Wang, Ching-Kun
    CANCER RESEARCH, 2024, 84 (06)
  • [27] Combination Treatment of Venetoclax and Hypomethylating Agents (HMA) or Low-Dose Cytarabine (LDAC) for Patients with Acute Myeloid Leukemia (AML) - Real-World Data from Two German Academic Centers
    Schmalbrock, Laura K.
    Braitsch, Krischan
    Jung, Paul
    Bumeder, Irmgard
    Kiewe, Philipp
    Westermann, Joerg
    Bullinger, Lars
    Keller, Ulrich
    Bassermann, Florian
    Kroenke, Jan
    Rieger, Kathrin
    Goetze, Katharina S.
    BLOOD, 2021, 138
  • [28] Outcomes of Therapy with Venetoclax Combined with Hypomethylating Agents in Favorable-Risk Acute Myeloid Leukemia (AML)
    Arslan, Shukaib
    Zhang, Jianying
    Dhakal, Prajwal
    Moran, Jenna A.
    Naidoo, Nuthana
    Story, Jennifer Lombardi
    Pullarkat, Vinod A.
    Stein, Anthony S.
    Marcucci, Guido
    Yaghmour, George
    Bhatt, Vijaya R.
    Fathi, Amir T.
    Aldoss, Ibrahim
    BLOOD, 2020, 136
  • [29] Outcomes of Newly Diagnosed Acute Myeloid Leukemia Patients Treated With Hypomethylating Agents With or Without Venetoclax: A Propensity Score-Adjusted Cohort Study
    Mustafa Ali, Moaath K.
    Corley, Elizabeth M.
    Alharthy, Hanan
    Kline, Kathryn A. F.
    Law, Jennie Y.
    Lee, Seung Tae
    Niyongere, Sandrine
    Duong, Vu H.
    Emadi, Ashkan
    Baer, Maria R.
    FRONTIERS IN ONCOLOGY, 2022, 12
  • [30] Antifungal Prophylaxis in Newly Diagnosed Acute Myeloid Leukemia Treated with a Hypomethylating Agent and Venetoclax: A Real-World Experience in Pharmacovigilance
    Burke, Mary
    Sallman, David A.
    Denson, Ariel
    Nelson, Rebecca Jean
    Chan, Onyee
    Walker, Alison R.
    Padron, Eric
    Xie, Zhuoer
    Komrokji, Rami S.
    Lancet, Jeffrey
    Kuykendall, Andrew T.
    Tobon, Katherine
    Jain, Akriti Gupta
    Wang, Chen
    Al Ali, Najla H.
    BLOOD, 2023, 142
12345